Novartis Simulect Plus Triple Therapy Shows 21% Transplant Rejection Rate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adding Novartis’ monoclonal antibody therapy Simulect to a triple immunosuppressive regimen for prophylaxis of renal transplant rejection resulted in a 21% rate of acute rejection in the first six months following transplant compared to a 35% rate for placebo plus triple therapy, labeling states.